RNTX
Rein Therapeutics announces preliminary Phase 2 IPF data for LTI-03
Rein Therapeutics reported preliminary Phase 2 blinded data for LTI-03 in idiopathic pulmonary fibrosis, showing an improvement in FVC for 33% of patients. The company also provided a business update noting 75% study enrollment.
Earnings|Guidance|M&A|Buyback|Dividend|Leadership|Restructuring|Regulatory|Legal|Cyber|Offering|Bankruptcy|Other
Nov 16, 2026
sentiment +0.30
SEC filing ↗
BriefTape provides AI-summarized public SEC filings for informational purposes only. Content does not constitute investment advice. Always verify against source filings at sec.gov. BriefTape is not a registered investment adviser, broker-dealer, or financial advisor.